Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 496,847
  • Shares Outstanding, K 61,415
  • Annual Sales, $ 0 K
  • Annual Income, $ -215,790 K
  • 60-Month Beta 1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33
Trade REPL with:

Options Overview Details

View History
  • Implied Volatility 89.74% ( -1.30%)
  • Historical Volatility 117.91%
  • IV Percentile 25%
  • IV Rank 13.44%
  • IV High 342.19% on 10/20/23
  • IV Low 50.54% on 08/15/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 125
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 1,601
  • Open Int (30-Day) 1,702

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.88
  • Number of Estimates 6
  • High Estimate -0.70
  • Low Estimate -1.10
  • Prior Year -0.75
  • Growth Rate Est. (year over year) -17.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.66 +43.11%
on 06/06/24
9.76 -16.97%
on 06/13/24
+2.54 (+45.68%)
since 06/05/24
3-Month
4.92 +64.63%
on 05/29/24
9.76 -16.97%
on 06/13/24
+0.74 (+10.05%)
since 04/05/24
52-Week
4.92 +64.63%
on 05/29/24
22.21 -63.53%
on 07/19/23
-14.08 (-63.48%)
since 07/05/23

Most Recent Stories

More News
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

This billionaire-guided hedge fund went bargain-shopping in the second quarter.

AFMD : 5.03 (-1.28%)
CERS : 1.7000 (-1.16%)
REPL : 8.11 (+0.25%)
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous...

REPL : 8.11 (+0.25%)
Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

REPL : 8.11 (+0.25%)
Replimune Announces the Departure of Jason Rhodes from its Board of Directors

WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

REPL : 8.11 (+0.25%)
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab),...

REPL : 8.11 (+0.25%)
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update

Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data...

REPL : 8.11 (+0.25%)
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies

RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC);...

REPL : 8.11 (+0.25%)
Replimune Group Enters Oversold Territory (REPL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

REPL : 8.11 (+0.25%)
Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

REPL : 8.11 (+0.25%)
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 naïve non-melanoma skin...

REPL : 8.11 (+0.25%)

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United...

See More

Key Turning Points

3rd Resistance Point 8.96
2nd Resistance Point 8.73
1st Resistance Point 8.41
Last Price 8.11
1st Support Level 7.86
2nd Support Level 7.63
3rd Support Level 7.31

See More

52-Week High 22.21
Fibonacci 61.8% 15.61
Fibonacci 50% 13.56
Fibonacci 38.2% 11.52
Last Price 8.11
52-Week Low 4.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar